GSK-Vir COVID-19 Antibody Muscle Injection as Effective as Intravenous Injection – Community News
Covid-19

GSK-Vir COVID-19 Antibody Muscle Injection as Effective as Intravenous Injection

A GlaxoSmithKline (GSK) logo is on display at GSK’s research center in Stevenage, UK, Nov. 26, 2019. REUTERS/Peter Nicholls/File Photo

Nov. 12 (Reuters) – Britain’s GSK (GSK.L) and partner Vir (VIR.O) said on Friday that their antibody-based COVID-19 therapy met the primary goal of a late-state study investigating intramuscular administration of the drug. was assessed as a treatment for early-stage disease.

The study showed that the treatment, sotrovimab, when injected into muscle was as good as when given intravenously for early treatment of mild to moderate COVID-19 in high-risk, non-hospitalized adults and adolescents.

The results offer opportunities to make the treatment more widely available.

Reporting by Muhammed Husain and Pushkala Aripaka in Bengaluru; Editing by Shinjini Ganguli

Our Standards: The Thomson Reuters Trust Principles.

About the author

Rakesh

Add Comment

Click here to post a comment